Last reviewed · How we verify
TLL-018 tablets
TLL-018 tablets' mechanism of action is not publicly available.
At a glance
| Generic name | TLL-018 tablets |
|---|---|
| Sponsor | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Due to limited information, the exact mechanism of TLL-018 tablets cannot be described.
Approved indications
Common side effects
Key clinical trials
- A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis (PHASE3)
- A Study of Efficacy and Safety of TLL-018 in CSU Participants (PHASE3)
- The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis (PHASE2)
- Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. (PHASE1)
- Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects (PHASE1)
- A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (PHASE3)
- Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis (PHASE1)
- The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |